Logo image of STAA

STAAR SURGICAL CO (STAA) Stock Fundamental Analysis

NASDAQ:STAA - Nasdaq - US8523123052 - Common Stock - Currency: USD

19.03  +0.69 (+3.76%)

After market: 19.03 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to STAA. STAA was compared to 189 industry peers in the Health Care Equipment & Supplies industry. While STAA has a great health rating, its profitability is only average at the moment. While showing a medium growth rate, STAA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year STAA was profitable.
STAA had a positive operating cash flow in the past year.
Of the past 5 years STAA 4 years were profitable.
In the past 5 years STAA always reported a positive cash flow from operatings.
STAA Yearly Net Income VS EBIT VS OCF VS FCFSTAA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

STAA's Return On Assets of -3.97% is fine compared to the rest of the industry. STAA outperforms 66.14% of its industry peers.
STAA has a Return On Equity of -5.09%. This is in the better half of the industry: STAA outperforms 70.37% of its industry peers.
Industry RankSector Rank
ROA -3.97%
ROE -5.09%
ROIC N/A
ROA(3y)3.25%
ROA(5y)3.83%
ROE(3y)4.04%
ROE(5y)4.92%
ROIC(3y)N/A
ROIC(5y)N/A
STAA Yearly ROA, ROE, ROICSTAA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

The Gross Margin of STAA (76.32%) is better than 88.89% of its industry peers.
In the last couple of years the Gross Margin of STAA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for STAA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.47%
STAA Yearly Profit, Operating, Gross MarginsSTAA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

STAA does not have a ROIC to compare to the WACC, probably because it is not profitable.
STAA has more shares outstanding than it did 1 year ago.
STAA has more shares outstanding than it did 5 years ago.
STAA has a better debt/assets ratio than last year.
STAA Yearly Shares OutstandingSTAA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
STAA Yearly Total Debt VS Total AssetsSTAA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 5.89 indicates that STAA is not in any danger for bankruptcy at the moment.
STAA's Altman-Z score of 5.89 is amongst the best of the industry. STAA outperforms 83.07% of its industry peers.
There is no outstanding debt for STAA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.89
ROIC/WACCN/A
WACC8.9%
STAA Yearly LT Debt VS Equity VS FCFSTAA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

STAA has a Current Ratio of 5.23. This indicates that STAA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.23, STAA is in the better half of the industry, outperforming 75.66% of the companies in the same industry.
A Quick Ratio of 4.62 indicates that STAA has no problem at all paying its short term obligations.
STAA has a better Quick ratio (4.62) than 77.78% of its industry peers.
Industry RankSector Rank
Current Ratio 5.23
Quick Ratio 4.62
STAA Yearly Current Assets VS Current LiabilitesSTAA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for STAA have decreased strongly by -45.00% in the last year.
The Earnings Per Share has been growing slightly by 7.49% on average over the past years.
Looking at the last year, STAA shows a decrease in Revenue. The Revenue has decreased by -2.64% in the last year.
The Revenue has been growing by 15.88% on average over the past years. This is quite good.
EPS 1Y (TTM)-45%
EPS 3Y-12.35%
EPS 5Y7.49%
EPS Q2Q%-484.62%
Revenue 1Y (TTM)-2.64%
Revenue growth 3Y10.84%
Revenue growth 5Y15.88%
Sales Q2Q%-35.82%

3.2 Future

STAA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.94% yearly.
STAA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.99% yearly.
EPS Next Y-373.06%
EPS Next 2Y-33.56%
EPS Next 3Y-16.26%
EPS Next 5Y16.94%
Revenue Next Year-23.89%
Revenue Next 2Y-2%
Revenue Next 3Y-1.77%
Revenue Next 5Y2.99%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
STAA Yearly Revenue VS EstimatesSTAA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
STAA Yearly EPS VS EstimatesSTAA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 57.67 indicates a quite expensive valuation of STAA.
Based on the Price/Earnings ratio, STAA is valued a bit cheaper than 67.72% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.22, STAA is valued quite expensively.
The Forward Price/Earnings Ratio is negative for STAA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 57.67
Fwd PE N/A
STAA Price Earnings VS Forward Price EarningsSTAA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STAA Per share dataSTAA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

STAA's earnings are expected to decrease with -16.26% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)7.7
EPS Next 2Y-33.56%
EPS Next 3Y-16.26%

More info and screens

0

5. Dividend

5.1 Amount

STAA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STAAR SURGICAL CO

NASDAQ:STAA (5/2/2025, 4:42:16 PM)

After market: 19.03 0 (0%)

19.03

+0.69 (+3.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners100.92%
Inst Owner Change0.02%
Ins Owners0.42%
Ins Owner Change18.94%
Market Cap938.75M
Analysts71.58
Price Target22.51 (18.29%)
Short Float %12.68%
Short Ratio5.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1639.16%
Min EPS beat(2)-3398.76%
Max EPS beat(2)120.44%
EPS beat(4)3
Avg EPS beat(4)-787.98%
Min EPS beat(4)-3398.76%
Max EPS beat(4)120.44%
EPS beat(8)5
Avg EPS beat(8)-382.88%
EPS beat(12)9
Avg EPS beat(12)-223.81%
EPS beat(16)12
Avg EPS beat(16)-47.33%
Revenue beat(2)0
Avg Revenue beat(2)-18.98%
Min Revenue beat(2)-37.91%
Max Revenue beat(2)-0.06%
Revenue beat(4)2
Avg Revenue beat(4)-8.86%
Min Revenue beat(4)-37.91%
Max Revenue beat(4)1.96%
Revenue beat(8)3
Avg Revenue beat(8)-4.18%
Revenue beat(12)4
Avg Revenue beat(12)-2.88%
Revenue beat(16)6
Avg Revenue beat(16)-0.58%
PT rev (1m)0%
PT rev (3m)-47.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-624.07%
EPS NY rev (1m)0%
EPS NY rev (3m)-210.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-51.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-31.15%
Valuation
Industry RankSector Rank
PE 57.67
Fwd PE N/A
P/S 2.99
P/FCF N/A
P/OCF 59.7
P/B 2.36
P/tB 2.37
EV/EBITDA N/A
EPS(TTM)0.33
EY1.73%
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)0.32
OCFY1.68%
SpS6.36
BVpS8.05
TBVpS8.02
PEG (NY)N/A
PEG (5Y)7.7
Profitability
Industry RankSector Rank
ROA -3.97%
ROE -5.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.32%
FCFM N/A
ROA(3y)3.25%
ROA(5y)3.83%
ROE(3y)4.04%
ROE(5y)4.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.47%
F-Score3
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 339.49%
Cap/Sales 7.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.23
Quick Ratio 4.62
Altman-Z 5.89
F-Score3
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)365.33%
Cap/Depr(5y)348.39%
Cap/Sales(3y)6.49%
Cap/Sales(5y)6.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45%
EPS 3Y-12.35%
EPS 5Y7.49%
EPS Q2Q%-484.62%
EPS Next Y-373.06%
EPS Next 2Y-33.56%
EPS Next 3Y-16.26%
EPS Next 5Y16.94%
Revenue 1Y (TTM)-2.64%
Revenue growth 3Y10.84%
Revenue growth 5Y15.88%
Sales Q2Q%-35.82%
Revenue Next Year-23.89%
Revenue Next 2Y-2%
Revenue Next 3Y-1.77%
Revenue Next 5Y2.99%
EBIT growth 1Y-144.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-644.94%
EBIT Next 3Y74.5%
EBIT Next 5Y61.9%
FCF growth 1Y-113.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.75%
OCF growth 3Y-29.01%
OCF growth 5Y-9.43%